personalized medicine

  • April 2, 2020  
  • March 7, 2019  

    Researchers Tap Genomic Technology to Develop Personalized Treatments for Pediatric Glioma Bookmark

    Emma Shtivelman, PhD

    Excerpt:

    “Researchers at UCSF Benioff Children’s Hospitals are using next-generation genomic technology to develop targeted therapies for high-grade pediatric glioma.

    “Sabine Mueller, MD, PhD, adjunct associate professor of neurology, pediatrics and neurosurgery at University of California, San Francisco, and colleagues aim to treat as many as 44 children and young adults with this disease.”

    Go to full article published by Healio on Feb 3, 2019.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • March 5, 2019  
  • February 3, 2017  
  • September 9, 2015  

    To PD-L1 or Not to PD-L1: That Is the Question

    Emma Shtivelman, PhD

    These days, it seems that I write mostly about immune checkpoint blockade drugs, or some other new immunotherapy treatment for cancer. This post is no different—it covers PD-L1, a protein that is at the center of clinical decisions for selecting patients who are likely to benefit from treatment with an anti-PD-1 or anti-PD-L1 drug.

  • August 13, 2015  

    What Determines Whether a Melanoma Patient Will Respond to Checkpoint Blockade Drugs?

    Emma Shtivelman, PhD

    Of all cancer types, melanoma is the most investigated in terms of its potential to be treated through immune system-based approaches. More immunotherapy drugs are approved for melanoma than for any other type of cancer, and more are in development. Recent additions to the immunotherapy arsenal are the ‘anti-PD-1’ immune checkpoint blockade drugs pembrolizumab (Keytruda) and nivolumab (Opdivo).